MoFo Life Sciences

September 13, 2022 - Agtech, United Kingdom, Regulatory
Key Considerations for Early-Stage Companies in the Alternative Protein Industry
By: Simon Arlington and Michelle Si-Ting Luo
Companies in the UK are regulated by many statutes, ranging from those dictating how much tax they need to pay, to those centred on how they treat their employees. At a corporate level, the main statute that companies should be familiar with is the
... ›
May 20, 2021 - United Kingdom, Regulatory
UK’s new emissions trading scheme hosts first auctions
By: Liz Freeman Rosenzweig Ph.D. and David H. Kaufman
Stephanie Pong , London trainee solicitor contributed to the writing of this article. On January 1, 2021, the UK launched its very own emissions trading scheme (the “UK ETS”) exercising its autonomy since departing the EU. Under this scheme, companies operating in certain sectors
... ›
April 08, 2021 - United States, FDA, Medical Devices + Diagnostics, United Kingdom, European Union, Regulatory
Global HealthTech CEO Connect: Software as a Medical Device in the U.S. and EU Recap
By: Wolfgang Schönig
On Friday, March 26, 2021, over 180 attendees worldwide attended McKinsey & Company’s first Global HealthTech CEO Connect of 2021. The discussion focused on regulatory and legal considerations for software as a medical device (SaMD) in both the United States and Europe and specific
... ›
March 02, 2021 - COVID-19, United Kingdom, European Union, Healthcare, Pharma
COVID-19: State Intervention in Times of Vaccine Shortages
By: Robert Grohmann
The European Union (“EU”) and its Member States are struggling with the pace of their vaccination programs. This is partly due to shortages of vaccine availability. Germany, like the rest of the EU, is scrambling to obtain vaccine doses as the pharmaceutical industry slows
... ›
February 24, 2021 - Medical Devices + Diagnostics, United Kingdom, Healthcare, Pharma, Regulatory
Life Sciences Regulatory Framework Becomes Law Post-Brexit
By: Jenny Galloway
Nearly one year after its introduction to the House of Commons, the Medicines and Medical Devices Bill 2019‑2021 (the Bill) was granted Royal Assent on 11 February 2021, becoming law as the Medicines and Medical Devices Act 2021 (the Act). The purpose of the Act is
... ›
November 17, 2020 - United States, Corporate + Venture Capital, United Kingdom, Startup, Intellectual Property
GSAS Harvard Biotech Club and Morrison & Foerster’s New Course
By: Andrew Boyd, Alfredo B. D. Silva, Anita Choi and Michael Ward Ph.D.
MoFo & GSAS Harvard Biotech Club’s new course, “ Legal Topics for Scientists, Entrepreneurs, and Start Ups ,” started on November 11, with more than 100 life sciences graduate students, post-docs, and industry professionals. The Harvard Biotech Club is a student organization that seeks to
... ›
November 13, 2020 - Medical Devices + Diagnostics, United Kingdom, Healthcare, Pharma, Regulatory
UK Plans for Robust Life Sciences Regulation Post-Brexit
By: Wolfgang Schönig
As Brexit is finally completed in the UK, from 1 January 2021, the Medicines and Healthcare products Regulatory Agency (“MHRA”) will be the UK’s standalone medicines and medical devices regulator. Transition from the EU allows the UK to offer fully independent regulatory decisions for
... ›
May 06, 2020 - United States, COVID-19, United Kingdom, European Union, Intellectual Property
Patent Offices Extend Certain Deadlines, but Proceed With Caution
Patent applicants facing a funds shortage because of COVID-19 may be glad to hear that many patent offices have extended certain patent prosecution deadlines. For example, the U.S. Patent Office has extended various patent deadlines until June 1, 2020 and the European Patent Office
... ›
April 16, 2020 - United States, COVID-19, United Kingdom, European Union, Healthcare, Intellectual Property
Germany, UK, USA: Are Patent Exceptions the Cure to COVID-19?
By: Wolfgang Schönig, Alistair Maughan and Robert Grohmann
As the COVID-19 pandemic continues to spread globally, the life sciences industry is at the forefront of addressing the urgent need for pharmaceuticals, diagnostics, ventilators, and personal protective equipment capable of helping to contain the surge. While the laws of many countries provide for
... ›

Topic Archives: United Kingdom

Key Considerations for Early-Stage Companies in the Alternative Protein Industry

By: Simon Arlington and Michelle Si-Ting Luo

UK’s new emissions trading scheme hosts first auctions

By: Liz Freeman Rosenzweig Ph.D. and David H. Kaufman

Global HealthTech CEO Connect: Software as a Medical Device in the U.S. and EU Recap

By: Wolfgang Schönig

COVID-19: State Intervention in Times of Vaccine Shortages

By: Robert Grohmann

Life Sciences Regulatory Framework Becomes Law Post-Brexit

By: Jenny Galloway

GSAS Harvard Biotech Club and Morrison & Foerster’s New Course

By: Andrew Boyd, Alfredo B. D. Silva, Anita Choi and Michael Ward Ph.D.

UK Plans for Robust Life Sciences Regulation Post-Brexit

By: Wolfgang Schönig

Patent Offices Extend Certain Deadlines, but Proceed With Caution

Germany, UK, USA: Are Patent Exceptions the Cure to COVID-19?

By: Wolfgang Schönig, Alistair Maughan and Robert Grohmann